Literature DB >> 32285687

Risk factors and prognosis of bone metastases in newly diagnosed gastric cancer.

Chengtong Liang1, Hui Chen2, Zhanjun Yang3, Chongxu Han4, Chuanli Ren4,5.   

Abstract

Aim: To predict the occurrence of bone metastases and prognosis among patients with gastric cancer on a population level. Materials & methods: Data were obtained from the SEER database (2010-2016). Multivariable logistic regression and multivariable Cox regression were used to determine factors that predict the occurrence of bone metastasis and prognosis.
Results: Cardia cancer, younger age, white race, poor differentiation grade, higher N stage, diffuse-type were positively associated with the presence of bone metastasis. For gastric cancer patients with bone metastasis, the median survival time was longer (9.0 months) among patients with surgery of primary site compared with those without surgery (3.0 months).
Conclusion: According to the results of risk assessment, clinical efforts should be targeted to focus on screening high-risk patients.

Entities:  

Keywords:  bone metastases; cohort study; gastric cancer; prognosis; risk factors

Mesh:

Year:  2020        PMID: 32285687     DOI: 10.2217/fon-2019-0728

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

1.  The incidence, risk factors and predictive nomograms for early death among patients with stage IV gastric cancer: a population-based study.

Authors:  Yi Yang; Zi-Jiao Chen; Su Yan
Journal:  J Gastrointest Oncol       Date:  2020-10

2.  Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification: A case report.

Authors:  Mingsheng Liu
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

Review 3.  Tumor Microenvironment, Clinical Features, and Advances in Therapy for Bone Metastasis in Gastric Cancer.

Authors:  Pengcheng Sun; Samuel O Antwi; Kurt Sartorius; Xiao Zheng; Xiaodong Li
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.